Home / Stock ratings / SANA

Stock rating · Biological Products, (No Diagnostic Substances)

Sana Biotechnology, Inc. (SANA) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Sana Biotechnology, Inc. 47 out of 100 (Promising). Its highest factor score is analyst sentiment at 94, and its lowest is price momentum at 8.

MELANY ratingRated 2026-11-20

SANA · composite score

47/100
Promising
Nov 20
Rating date
Live price in the app →
Quality50
Momentum8
Risk-adjusted25
Source basis SEC filings and live market dataDated snapshot

About Sana Biotechnology, Inc.

Sana Biotechnology Inc is a biotechnology company that develops engineered cells as medicines and therapies. Its cell engineering programs span several therapeutic areas with unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disease, and central nervous system (CNS) disorders, with a candidate pipeline that includes SC291, SC262, UP421, and others.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why SANA scores 47/100

SANA's 8 factor scores run from 8 to 94, and 5 of them sit above its composite of 47. Here is how SANA breaks down.

Valuation65/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality50/100

Margins, returns on capital, and balance-sheet strength.

Price momentum8/100

Direction and relative strength of the recent share-price trend.

Earnings track record80/100

History of beating or missing estimates, and where estimates are heading.

  • Avg EPS beat +11%
Analyst sentiment94/100

What Wall Street price targets and revisions are signalling.

  • Analyst targets 430% upside
  • Institutional net buying +15.5%
Catalyst setup36/100

Near-term events that could move the stock.

Risk-adjusted profile25/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How SANA compares

As of November 20, 2026, Sana Biotechnology, Inc. ranks 7th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53.

All stock rating pages.

Key risks for SANA

  • Negative free cash flow, company consuming cash, not generating it
  • Short interest 23% of float, high volatility risk on news
  • Weak price momentum, trend not yet confirmed, may need more time to set up
  • High beta 2.3, amplifies market drawdowns 1.8x+ in selloffs
  • Performance partly driven by Healthcare sector, rotation away from this theme would hurt

Sector and theme context

Sana Biotechnology, Inc. sits in the Healthcare sector theme, which MELANY currently rates 99/100 for strength. Theme strength feeds SANA's momentum and catalyst factors above.

SANA trade plan (Pro)

MELANY has a full position plan for Sana Biotechnology, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates SANA

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Sana Biotechnology, Inc.'s 47/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about SANA

Is Sana Biotechnology, Inc. (SANA) a buy?

As of 2026-11-20, MELANY rated Sana Biotechnology, Inc. Promising with a composite score of 47/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does SANA rank against similar companies?

As of November 20, 2026, Sana Biotechnology, Inc. ranks 7th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 53. Among the other names in the group, the highest scores belong to AMGN (62) and BIIB (60).

Should I buy Sana Biotechnology, Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Sana Biotechnology, Inc. (SANA) Promising with a composite of 47/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the SANA stock price forecast?

MELANY does not publish price targets or forecasts for SANA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 47/100 across eight factors for Sana Biotechnology, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for SANA as of 2026-11-20: its analyst sentiment factor is 94/100 (Analyst targets 430% upside), and its price momentum factor is 8/100.

Is SANA stock overvalued or undervalued?

MELANY's valuation factor currently reads 65/100 for Sana Biotechnology, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SANA's read.

What price should I buy SANA at?

Rather than chasing the current price, MELANY computes a smart entry zone for SANA: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying SANA stock?

The top risks MELANY currently flags for Sana Biotechnology, Inc.: Negative free cash flow, company consuming cash, not generating it; Short interest 23% of float, high volatility risk on news; Weak price momentum, trend not yet confirmed, may need more time to set up; High beta 2.3, amplifies market drawdowns 1.8x+ in selloffs; Performance partly driven by Healthcare sector, rotation away from this theme would hurt. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Sana Biotechnology, Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 50/100 for Sana Biotechnology, Inc., and earnings track record, at 80/100. The 47/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will SANA stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 8/100 for SANA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this SANA rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores SANA as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, SANA included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.